The Prostate

Cover image for Vol. 76 Issue 12

Early View (Online Version of Record published before inclusion in an issue)

Edited By: John T. Isaacs

Impact Factor: 3.778

ISI Journal Citation Reports © Ranking: 2015: 13/77 (Urology & Nephrology); 37/131 (Endocrinology & Metabolism)

Online ISSN: 1097-0045

VIEW

  1. 1 - 38
  1. Original Articles

    1. Benign Prostatic Hyperplasia, Metabolic Syndrome and Non-Alcoholic Fatty Liver Disease: Is Metaflammation the Link?

      Giorgio Ivan Russo, Sebastiano Cimino, Tommaso Castelli, Vincenzo Favilla, Mauro Gacci, Marco Carini, Rosita A. Condorelli, Sandro La Vignera, Aldo E. Calogero, Fabio Motta, Lidia Puzzo, Rosario Caltabiano and Giuseppe Morgia

      Version of Record online: 25 JUL 2016 | DOI: 10.1002/pros.23237

    2. Orteronel Switch Maintenance Therapy in Metastatic Castration Resistant Prostate Cancer After First-Line Docetaxel: A Multicenter, Randomized, Double-Blind, Placebo-Controlled Trial (SAKK 08/11)

      Richard Cathomas, Simon J. Crabb, Michael Mark, Ralph Winterhalder, Christian Rothermundt, Tony Elliott, Philippe von Burg, Heike Kenner, Stefanie Hayoz, Simona Berardi Vilei, Daniel Rauch, Enrico Roggero, Markus G. Mohaupt, Jürg Bernhard, Gabriela Manetsch, Silke Gillessen and for the Swiss Group for Clinical Cancer Research SAKK

      Version of Record online: 25 JUL 2016 | DOI: 10.1002/pros.23236

    3. Increased urinary adenosine triphosphate in patients with bladder outlet obstruction due to benign prostate hyperplasia

      Miguel Silva-Ramos, Isabel Silva, José Carlos Oliveira and Paulo Correia-de-Sá

      Version of Record online: 15 JUL 2016 | DOI: 10.1002/pros.23207

    4. Inhibition of adrenergic and non-adrenergic smooth muscle contraction in the human prostate by the phosphodiesterase 10-selective inhibitor TC-E 5005

      Martin Hennenberg, Melanie Schott, Aysenur Kan, Patrick Keller, Alexander Tamalunas, Anna Ciotkowska, Beata Rutz, Yiming Wang, Frank Strittmatter, Annika Herlemann, Qingfeng Yu, Christian G. Stief and Christian Gratzke

      Version of Record online: 15 JUL 2016 | DOI: 10.1002/pros.23208

  2. Letters to the Editor

    1. Incorrect analysis of MCAM gene promoter methylation in prostate cancer

      Kinga A. Kocemba, Paulina Dudzik, Barbara Ostrowska and Piotr Laidler

      Version of Record online: 15 JUL 2016 | DOI: 10.1002/pros.23210

  3. Original Articles

    1. Heteronemin Is a Novel c-Met/STAT3 Inhibitor Against Advanced Prostate Cancer Cells

      Jian-Ching Wu, Chiang-Ting Wang, Han-Chun Hung, Wen-Jeng Wu, Deng-Chyang Wu, Min-Chi Chang, Ping-Jyun Sung, Yu-Wei Chou, Zhi-Hong Wen and Ming-Hong Tai

      Version of Record online: 15 JUL 2016 | DOI: 10.1002/pros.23230

    2. Neuronal trans-differentiation in prostate cancer cells

      Andrew Farach, Yi Ding, MinJae Lee, Chad Creighton, Nikki A. Delk, Michael Ittmann, Brian Miles, David Rowley, Mary C. Farach-Carson and Gustavo E. Ayala

      Version of Record online: 12 JUL 2016 | DOI: 10.1002/pros.23221

    3. You have full text access to this OnlineOpen article
      Accumulation of palmitoylcarnitine and its effect on pro-inflammatory pathways and calcium influx in prostate cancer

      Ala'a Al-Bakheit, Maria Traka, Shikha Saha, Richard Mithen and Antonietta Melchini

      Version of Record online: 12 JUL 2016 | DOI: 10.1002/pros.23222

    4. You have full text access to this OnlineOpen article
      The relationship between metformin and serum prostate-specific antigen levels

      Viranda H. Jayalath, Christopher Ireland, Neil E. Fleshner, Robert J. Hamilton and David J.A. Jenkins

      Version of Record online: 12 JUL 2016 | DOI: 10.1002/pros.23228

    5. Clinical significance of proliferative inflammatory atrophy in negative prostatic biopsies

      Pol Servian, Ana Celma, Jacques Planas, José Placer, Inés M. de Torres and Juan Morote

      Version of Record online: 12 JUL 2016 | DOI: 10.1002/pros.23234

  4. Erratum

    1. You have free access to this content
      Erratum

      Version of Record online: 24 JUN 2016 | DOI: 10.1002/pros.23231

      This article corrects:
  5. Original Articles

    1. Schiff base-poloxamer P85 combination prevents prostate cancer progression in C57/Bl6 mice

      Ayşegül Doğan, Selami Demirci, Neşe Başak Türkmen, Ahmet Burak Çağlayan, Safa Aydın, Dilek Telci, Ertuğrul Kılıç, Kazım Şahin, Cemal Orhan, Mehmet Tuzcu, Asiye Işın Doğan Ekici and Fikrettin Şahin

      Version of Record online: 24 JUN 2016 | DOI: 10.1002/pros.23229

    2. Effect of dietary omega-3 fatty acids on tumor-associated macrophages and prostate cancer progression

      Pei Liang, Susanne M. Henning, Shiruyeh Schokrpur, Lily Wu, Ngan Doan, Jonathan Said, Tristan Grogan, David Elashoff, Pinchas Cohen and William J. Aronson

      Version of Record online: 24 JUN 2016 | DOI: 10.1002/pros.23218

    3. Bipolar androgen therapy for men with androgen ablation naïve prostate cancer: Results from the phase II BATMAN study

      Michael T. Schweizer, Hao Wang, Brandon Luber, Rosa Nadal, Avery Spitz, D. Marc Rosen, Haiyi Cao, Emmanuel S. Antonarakis, Mario A. Eisenberger, Michael A. Carducci, Channing Paller and Samuel R. Denmeade

      Version of Record online: 24 JUN 2016 | DOI: 10.1002/pros.23209

    4. Phase I trial of anti-PSMA designer CAR-T cells in prostate cancer: Possible role for interacting interleukin 2-T cell pharmacodynamics as a determinant of clinical response

      Richard P. Junghans, Qiangzhong Ma, Ritesh Rathore, Erica M. Gomes, Anthony J. Bais, Agnes S.Y. Lo, Mehrdad Abedi, Robin A. Davies, Howard J. Cabral, A. Samer Al-Homsi and Stephen I. Cohen

      Version of Record online: 21 JUN 2016 | DOI: 10.1002/pros.23214

    5. A pilot study of clinical targeted next generation sequencing for prostate cancer: Consequences for treatment and genetic counseling

      Heather H. Cheng, Nola Klemfuss, Bruce Montgomery, Celestia S. Higano, Michael T. Schweizer, Elahe A. Mostaghel, Lisa G. McFerrin, Evan Y. Yu, Peter S. Nelson and Colin C. Pritchard

      Version of Record online: 21 JUN 2016 | DOI: 10.1002/pros.23219

  6. Rapid Communication

    1. A genetic variation of SOD2 does not determine duration of response to androgen deprivation therapy for prostate cancer

      Wanling Xie, Sarah Drouin, Mari Nakabayashi, Mark Pomerantz, Gwo-Shu Mary Lee, Philip W. Kantoff and Nima Sharifi

      Version of Record online: 21 JUN 2016 | DOI: 10.1002/pros.23220

  7. Original Articles

    1. Peripheral zone inflammation is not strongly associated with lower urinary tract symptom incidence and progression in the placebo arm of the prostate cancer prevention trial

      Ibrahim Kulac, Berrak Gumuskaya, Charles G. Drake, Beverly Gonzalez, Kathryn B. Arnold, Phyllis J. Goodman, Alan R. Kristal, M. Scott Lucia, Ian M. Thompson, William B. Isaacs, Angelo M. De Marzo and Elizabeth A. Platz

      Version of Record online: 21 JUN 2016 | DOI: 10.1002/pros.23224

    2. Monomethyl auristatin e phosphate inhibits human prostate cancer growth

      David Cunningham, Keshab R. Parajuli, Changde Zhang, Guangdi Wang, Jiandong Mei, Qiuyang Zhang, Sen Liu and Zongbing You

      Version of Record online: 21 JUN 2016 | DOI: 10.1002/pros.23226

    3. Loss of expression of AZGP1 is associated with worse clinical outcomes in a multi-institutional radical prostatectomy cohort

      James D. Brooks, Wei Wei, Jonathan R. Pollack, Robert B. West, Jun Ho Shin, John B. Sunwoo, Sarah J. Hawley, Heidi Auman, Lisa F. Newcomb, Jeff Simko, Antonio Hurtado-Coll, Dean A. Troyer, Peter R. Carroll, Martin E. Gleave, Daniel W. Lin, Peter S. Nelson, Ian M. Thompson, Lawrence D. True, Jesse K. McKenney, Ziding Feng and Ladan Fazli

      Version of Record online: 21 JUN 2016 | DOI: 10.1002/pros.23225

    4. The germ cell gene TDRD1 as an ERG target gene and a novel prostate cancer biomarker

      Lijuan Xiao, Rainer B. Lanz, Anna Frolov, Patricia D. Castro, Zheng Zhang, Baijun Dong, Wei Xue, Sung Yun Jung, John P. Lydon, Dean P. Edwards, Michael A. Mancini, Qin Feng, Michael M. Ittmann and Bin He

      Version of Record online: 8 JUN 2016 | DOI: 10.1002/pros.23213

    5. Novel gene expression signature predictive of clinical recurrence after radical prostatectomy in early stage prostate cancer patients

      Ahva Shahabi, Juan Pablo Lewinger, Jie Ren, Craig April, Andy E. Sherrod, Joseph G. Hacia, Siamak Daneshmand, Inderbir Gill, Jacek K. Pinski, Jian-Bing Fan and Mariana C. Stern

      Version of Record online: 8 JUN 2016 | DOI: 10.1002/pros.23211

    6. Mutational analysis of prostate-specific antigen defines the intrinsic proteolytic activity of the proPSA zymogen

      Niquiche Sangster-Guity, Becky Tu-Sekine, Daniel M. Raben, Samuel R. Denmeade and Simon A. Williams

      Version of Record online: 8 JUN 2016 | DOI: 10.1002/pros.23216

    7. A novel system for estimating residual disease and pathologic response to neoadjuvant treatment of prostate cancer

      Claire Murphy, Lawrence True, Funda Vakar-Lopez, Jing Xia, Roman Gulati, Bruce Montgomery and Maria Tretiakova

      Version of Record online: 8 JUN 2016 | DOI: 10.1002/pros.23215

  8. Review Articles

    1. Implications of high rates of metastatic prostate cancer in BRCA2 mutation carriers

      Stephanie Gleicher, Eric C. Kauffman, Leszek Kotula, Gennady Bratslavsky and Srinivas Vourganti

      Version of Record online: 26 MAY 2016 | DOI: 10.1002/pros.23204

  9. Original Articles

    1. Generation of a C57BL/6 MYC-driven mouse model and cell line of prostate cancer

      Leigh Ellis, ShengYu Ku, Qiuhui Li, Gissou Azabdaftari, Joseph Seliski, Brian Olson, Colleen S. Netherby, Dean G. Tang, Scott I. Abrams, David W. Goodrich and Roberto Pili

      Version of Record online: 26 MAY 2016 | DOI: 10.1002/pros.23206

    2. Regulation of miR-200c and miR-141 by methylation in prostate cancer

      Seodhna M. Lynch, Karla M. O'Neill, Michael M. McKenna, Colum P. Walsh and Declan J. McKenna

      Version of Record online: 16 MAY 2016 | DOI: 10.1002/pros.23201

    3. A 2-gene panel derived from prostate cancer-enhanced transcripts in whole blood is prognostic for survival and predicts treatment benefit in metastatic castration-resistant prostate cancer

      Matthias M. Heck, Mark Thalgott, Sebastian C. Schmid, William K. Oh, Yixuan Gong, Li Wang, Jun Zhu, Anna-Katharina Seitz, Desiree Porst, Michael Höppner, Margitta Retz, Jürgen E. Gschwend and Roman Nawroth

      Version of Record online: 16 MAY 2016 | DOI: 10.1002/pros.23202

    4. Nanoparticle-enabled selective destruction of prostate tumor using MRI-guided focal photothermal therapy

      Cheng S. Jin, Marta Overchuk, Liyang Cui, Brian C. Wilson, Robert G. Bristow, Juan Chen and Gang Zheng

      Version of Record online: 16 MAY 2016 | DOI: 10.1002/pros.23203

    5. You have full text access to this OnlineOpen article
      Impact of genetic and epigenetic variations within the FADS cluster on the composition and metabolism of polyunsaturated fatty acids in prostate cancer

      Tao Cui, Austin G. Hester, Michael C. Seeds, Elaheh Rahbar, Timothy D. Howard, Susan Sergeant and Floyd H. Chilton

      Version of Record online: 16 MAY 2016 | DOI: 10.1002/pros.23205

    6. Neoadjuvant Chemotherapy Using Reduced-Dose Docetaxel Followed by Radical Prostatectomy for Patients With Intermediate and High-Risk Prostate Cancer: A Single-Center Study

      Alexander Nosov, Sergey Reva, Sergey Petrov, Eldar Mamijev, Roman Novikov, Evgeniy Veliev, Florian Imkamp, Yuri Tolkach and Vladimir Moiseenko

      Version of Record online: 11 FEB 2016 | DOI: 10.1002/pros.23165

  10. Erratum

    1. You have free access to this content
      Erratum

      Version of Record online: 30 DEC 2015 | DOI: 10.1002/pros.23148

      This article corrects:

      Plateau effect of prostate cancer risk-associated SNPs in discriminating prostate biopsy outcomes

      Vol. 73, Issue 16, 1824–1835, Version of Record online: 26 AUG 2013

VIEW

  1. 1 - 38

SEARCH

SEARCH BY CITATION